Mumbai, Jul 26 (PTI) RPG Life Sciences has reported a marginal decline in profit after tax (PAT) for the June 2025 quarter at Rs 26.29 crore against Rs 26.76 crore a year ago, according to a regulatory filing.

Its revenue from operations for the reporting quarter, however, increased 2 per cent to Rs 168.92 crore from Rs 165.42 crore in Q1 FY25, the RPG group firm said.

Also Read | What Is Foot-and-Mouth Virus? All You Need To Know About FMD As It Kills 15 Spotted Deer at Pune Zoo.

"In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence," RPG Life Sciences Managing Director Ashok Nair said.

He said the company's domestic formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach.

Also Read | Indian Army Agniveer CEE Result 2025 Declared: Check How to Download Scorecard, Roll Number-Wise Merit List and Phase II Process Details at joinindianarmy.nic.in.

"We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach," Nair stated.

"We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders," Nair added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)